# Probiotics in Advanced Urothelial Carcinoma

> **NCT06904573** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 222 (estimated)

## Conditions studied

- Advanced Urothelial Carcinoma
- Probiotics
- Immunotherapy

## Interventions

- **DRUG:** Probiotics Compound (Biolosion)
- **DRUG:** Nab-paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Disitamab vedotin
- **DRUG:** Enfortumab Vedotin
- **DRUG:** Pembrolizumab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06904573
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904573, "Probiotics in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06904573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*